Results 71 to 80 of about 14,024 (212)

Do Not Anchor on Vasculitis: Pancreatic Cancer Presenting With Isolated Celiac/Superior Mesenteric Artery Thickening

ACR Open Rheumatology, Volume 8, Issue 4, April 2026.
Objective Medium‐vessel vasculitis involving the visceral vasculature in adults is rare. Pancreatic ductal adenocarcinoma (PDAC) has been implicated in medium artery vascular thickening secondary to extravascular migratory metastasis with involvement of the celiac and superior mesenteric vessels.
Maryam Own, Matthew J. Koster, Kenneth J. Warrington   +2 more
wiley   +1 more source

Dysautonomia in a cutaneous polyarteritis nodosa patient: evidence of systemic evolving? [PDF]

Beyond Rheumatology
Objective: We report a case of a patient with a cutaneous polyarteritis nodosa who developed dysautonomia and review this association's literature. Case report: A 75-year-old male patient was admitted with a recent history of recurrent ulcers on his ...
J. de Carvalho, T. Larocca Skare, Y. Shoenfeld   +2 more
doaj   +1 more source

Edoxaban‐induced enterocolitis: The first case report demonstrating distinct endoscopic and histological features

DEN Open, Volume 6, Issue 1, April 2026.
Abstract Direct oral anticoagulants (DOACs), including edoxaban, are widely used for stroke prevention in atrial fibrillation and venous thromboembolism. While gastrointestinal bleeding and diarrhea are recognized adverse effects, DOAC‐induced enterocolitis has not been established as a distinct clinical entity.
Katsuya Endo, Jun Yamada, Tomofumi Katayama, Yuki Yoshino, Daisuke Fukushi, Akinobu Koiwai, Takayuki Kogure, Morihisa Hirota, Kennichi Satoh   +8 more
wiley   +1 more source

Cutaneous polyarteritis nodosa treated with pentoxifylline and clobetasol propionate: A case report

Saudi Journal of Medicine and Medical Sciences, 2018
Cutaneous polyarteritis nodosa (cPAN) is a rare type of cutaneous vasculitis. It affects the small- and medium-sized arteries of the dermis and subcutaneous tissue without extracutaneous involvement.
Nada Abdulaziz A. Alquorain, Abdullah Salih H. Aljabr, Nada Juman Alghamdi   +2 more
doaj   +1 more source

Supplementary - Tocilizumab for polyarteritis nodosa

Tocilizumab for polyarteritis nodosa.
cottu, adrien
core   +1 more source

Renal infarction due to polyarteritis nodosa in a patient with angioimmunoblastic T-cell lymphoma: a case report and a brief review of the literature

Diagnostic Pathology, 2012
Angioimmunoblastic T-cell lymphoma is one of the most common subtypes of peripheral T-cell lymphoma (15-20% of all cases), accounting for approximately 1-2% of all non-Hodgkin lymphomas.
Ambrosio Maria, Rocca Bruno, Ginori Alessandro, Onorati Monica, Fabbri Alberto, Carmellini Mario, Lazzi Stefano, Tripodi Sergio   +7 more
doaj   +1 more source

Polyarteritis Nodosa [PDF]

Proceedings of the Royal Society of Medicine, 1956
E R, CULLINAN, R C, KING
openaire   +2 more sources

Polyarteritis nodosa

Acta Médica del Centro, 2012
Polyarteritis nodosa is a rare disease whose incidence is estimated at 4 to 10 cases per million persons, and mainly affects men between 40 and 60 years of age.
Gloria Catalina Bacallao Martínez, Carlos E. Lima León, Isabel González Alemán   +2 more
doaj  

Polyarteritis Nodosa with Bilateral Asynchronous Testicular Necrosis: A Case Report

Case Reports in Urology, 2011
Polyarteritis nodosa (PAN) is a systemic vasculitis which may result in thrombosis or aneurysm formation in any organ of the body. We report a case polyarteritis nodosa (PAN) resulting in bilateral asynchronous testicular necrosis.
Nicholas J. Toepfer, Nektarios I. Lountzis, Joseph C. Ugoeke, Tammie C. Ferringer   +3 more
doaj   +1 more source

Polyarteritis nodosa is an unforeseen borderline paradoxical adverse reaction in a female patient with rheumatoid arthritis treated with tofacitinib

Современная ревматология, 2019
The paper describes the occurrence of polyarteritis nodosa in a patient with rheumatoid arthritis during treatment with tofacitinib. It considers the reasons why this condition should be regarded as an unforeseen borderline paradoxical adverse reaction.
Yu. V. Muraviev, S. G. Radenska-Lopovok, V. V. Lebedeva, S. Yu. Alamankina   +3 more
doaj   +1 more source